Authors: Stephen J. McWilliam, Daniel J. Antoine, Venkata Sabbisetti, Mark A. Turner, Tracey Farragher, Joseph V. Bonventre, B. Kevin Park, Rosalind L. Smyth, Munir Pirmohamed
DOI: 10.1371/journal.pone.0043809
Abstract Summary
Novel urinary biomarkers, particularly KIM-1, can detect kidney damage from gentamicin treatment in premature infants. This proof-of-concept study of 41 preterm neonates demonstrates that non-invasive urine testing could enable early identification of antibiotic-related kidney toxicity, allowing timely treatment adjustments and better risk assessment.
Why Brain? đź§
Novel urinary biomarkers can detect early kidney damage from aminoglycoside antibiotics in premature babies, enabling treatment adjustments before serious harm occurs, with KIM-1 showing most promise.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
